Literature DB >> 21640963

Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors.

Dirk Michael Forner1, Bjoern Lampe.   

Abstract

OBJECTIVE: Whereas pelvic exenteration is an established therapy for the treatment of recurrent cervical carcinoma, it is not often performed for primary locally advanced cervical cancer (LACC). STUDY
DESIGN: This retrospective study analyzed survival data and prognostic factors of 35 patients with LACC who were treated by pelvic exenteration.
RESULTS: After surgery, 33 patients (97%) were macroscopically free of tumor. In 20 patients, pelvic lymph nodes (LN) were involved, and in 6 of these, metastatic tissue had reached the paraaortal nodes. Overall, the patients' mean 5 year survival was 43%, and the median survival time was 30 months; these values ranged from 15% to 70% and from 15 to 44 months, respectively, depending on LN involvement (P=.006). Pelvic LN involvement was the only significant factor for overall survival found in the multivariate analysis (P=.02).
CONCLUSION: In LACC with free LNs and no distant metastases, pelvic exenteration has good long-term results.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21640963     DOI: 10.1016/j.ajog.2011.03.057

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

2.  Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Authors:  Sota Tanaka; Satoru Nagase; Michiko Kaiho-Sakuma; Tomoyuki Nagai; Hiroki Kurosawa; Masafumi Toyoshima; Hideki Tokunaga; Takeo Otsuki; Hiroki Utsunomiya; Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

Review 3.  Pelvic exenteration--reconsidering the procedure.

Authors:  N Bacalbasa; I Balescu
Journal:  J Med Life       Date:  2015 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.